The relevance of Plk1 targeting with a non-clinically approved Plk1 inhibitor (BI 25366, intratumor injection, irrelevant for cancer patients) for ccRCC was described by an independent approach (gene expression profiling and RNAi screening)31. The gene discussed is PLK1; the disease is nonpapillary renal cell carcinoma.